Shares of biotech firm BridgeBio Pharma (BBIO) have been trending down in the past year, with a big decline recently. However, one trader sees a rebound in shares in the weeks ahead.
That’s based on the January $75 call options. With 50 days until expiration, over 11,795 contracts traded against a prior open interest of 119, for a 100-fold surge in volume. The buyer of the calls paid $2.22 to make the trade.
Shares recently traded around $40, so the $75 calls would require shares to rise at least $35, or 87 percent in the next 50 days. That would put shares on par with their 52-week high, but such a move would require some sort of catalyst to best play out.
- My #1 EV Stock (NOT Tesla)
I believe this little-known company will be the next EV giant.
Its car is faster than Ferrari's F8, McLaren's 720S and Porsche's 911 Turbo. Yet it's 100% electric.
And while it's a marvel of American engineering...The CEO wants it to be an everyman's car... and plans to ship out 1 million per year.
Already, it's set to grow faster than Tesla, Amazon and Facebook... COMBINED. Sales could DOUBLE to $5.5 billion in 2023... then almost double again to $9.9 billion a year after that.
Simply put, this company could be on the verge of a HUGE run.
As an early-stage biotech company working on breakthrough treatments, the company doesn’t make money and currently sits on big losses. However, a breakthrough could lead to a massive move higher in shares, and the possibility of a buyout from a larger pharma company.
Action to take: This trade could play out well on a year-end market rally, or some unexpected good news for the company. That makes it potentially interesting. Investors could also buy shares here and sell covered calls, given the massive premiums available.
For traders, the option could pay out huge in the weeks ahead, or could end up bleeding out. Those who buy should look for a short-term profit and look to close out the trade early to take advantage of this particularly unusual options buy here.
Disclosure: The author of this article has no position in the company mentioned here, but may trade after the next 72 hours. The author receives no compensation from any of the companies mentioned in this article.